

# Christopher R Triggles

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/146794/christopher-r-triggles-publications-by-year.pdf>

**Version:** 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

114  
papers

4,651  
citations

40  
h-index

65  
g-index

122  
ext. papers

5,307  
ext. citations

5.4  
avg, IF

5.82  
L-index

#	Paper	IF	Citations
114	3D Tissue-Engineered Vascular Drug Screening Platforms: Promise and Considerations.. <i>Frontiers in Cardiovascular Medicine</i> , <b>2022</b> , 9, 847554	5.4	4
113	Matching Drug Metabolites from Non-Targeted Metabolomics to Self-Reported Medication in the Qatar Biobank Study.. <i>Metabolites</i> , <b>2022</b> , 12,	5.6	1
112	COVID-19 Vaccines and Hyperglycemia-Is There a Need for Postvaccination Surveillance?. <i>Vaccines</i> , <b>2022</b> , 10,	5.3	2
111	Metformin: Is it a drug for all reasons and diseases?. <i>Metabolism: Clinical and Experimental</i> , <b>2022</b> , 155223	12.7	6
110	Requiem for impact factors and high publication charges. <i>Accountability in Research</i> , <b>2021</b> , 1-32	1.9	2
109	A Comprehensive Review of Viral Characteristics, Transmission, Pathophysiology, Immune Response, and Management of SARS-CoV-2 and COVID-19 as a Basis for Controlling the Pandemic. <i>Frontiers in Immunology</i> , <b>2021</b> , 12, 631139	8.4	43
108	Metformin Prevents Hyperglycemia-Associated, Oxidative Stress-Induced Vascular Endothelial Dysfunction: Essential Role for the Orphan Nuclear Receptor Human Nuclear Receptor 4A1 (Nur77). <i>Molecular Pharmacology</i> , <b>2021</b> , 100, 428-455	4.3	3
107	A Critical Review of the Evidence That Metformin Is a Putative Anti-Aging Drug That Enhances Healthspan and Extends Lifespan. <i>Frontiers in Endocrinology</i> , <b>2021</b> , 12, 718942	5.7	17
106	COVID-19: Learning from Lessons To Guide Treatment and Prevention Interventions. <i>MSphere</i> , <b>2020</b> , 5,	5	44
105	Why the endothelium? The endothelium as a target to reduce diabetes-associated vascular disease. <i>Canadian Journal of Physiology and Pharmacology</i> , <b>2020</b> , 98, 415-430	2.4	22
104	A Review of the Progress and Challenges of Developing a Vaccine for COVID-19. <i>Frontiers in Immunology</i> , <b>2020</b> , 11, 585354	8.4	189
103	Potent and PPAR $\beta$ -Independent anti-proliferative action of the hypolipidemic drug fenofibrate in VEGF-dependent angiosarcomas in vitro. <i>Scientific Reports</i> , <b>2019</b> , 9, 6316	4.9	8
102	Exercise Alleviates Obesity-Induced Metabolic Dysfunction via Enhancing FGF21 Sensitivity in Adipose Tissues. <i>Cell Reports</i> , <b>2019</b> , 26, 2738-2752.e4	10.6	51
101	Minimizing Hyperglycemia-Induced Vascular Endothelial Dysfunction by Inhibiting Endothelial Sodium-Glucose Cotransporter 2 and Attenuating Oxidative Stress: Implications for Treating Individuals With Type 2 Diabetes. <i>Canadian Journal of Diabetes</i> , <b>2019</b> , 43, 510-514	2.1	17
100	Treatment with a Combination of Metformin and 2-Deoxyglucose Upregulates Thrombospondin-1 in Microvascular Endothelial Cells: Implications in Anti-Angiogenic Cancer Therapy. <i>Cancers</i> , <b>2019</b> , 11,	6.6	18
99	Metformin: The Answer to Cancer in a Flower? Current Knowledge and Future Prospects of Metformin as an Anti-Cancer Agent in Breast Cancer. <i>Biomolecules</i> , <b>2019</b> , 9,	5.9	40
98	Impact of currently used anti-diabetic drugs on myoendothelial communication. <i>Current Opinion in Pharmacology</i> , <b>2019</b> , 45, 1-7	5.1	6

97	Hyperglycaemia disrupts conducted vasodilation in the resistance vasculature of db/db mice. <i>Vascular Pharmacology</i> , <b>2018</b> , 103-105, 29-35	5.9	11
96	Hyperglycaemic impairment of PAR2-mediated vasodilation: Prevention by inhibition of aortic endothelial sodium-glucose-co-Transporter-2 and minimizing oxidative stress. <i>Vascular Pharmacology</i> , <b>2018</b> , 109, 56-71	5.9	57
95	Metformin is not just an antihyperglycaemic drug but also has protective effects on the vascular endothelium. <i>Acta Physiologica</i> , <b>2017</b> , 219, 138-151	5.6	67
94	Metformin represses glucose starvation induced autophagic response in microvascular endothelial cells and promotes cell death. <i>Biochemical Pharmacology</i> , <b>2017</b> , 132, 118-132	6	27
93	From Gutenberg to Open Science: An Unfulfilled Odyssey. <i>Drug Development Research</i> , <b>2017</b> , 78, 3-23	5.1	10
92	Effects of oxidative and thermal stresses on stress granule formation in human induced pluripotent stem cells. <i>PLoS ONE</i> , <b>2017</b> , 12, e0182059	3.7	17
91	Molecular Interplay between microRNA-34a and Sirtuin1 in Hyperglycemia-Mediated Impaired Angiogenesis in Endothelial Cells: Effects of Metformin. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2016</b> , 356, 314-23	4.7	64
90	Metformin: An Old Drug for the Treatment of Diabetes but a New Drug for the Protection of the Endothelium. <i>Medical Principles and Practice</i> , <b>2015</b> , 24, 401-15	2.1	99
89	Fibroblast growth factor 21 prevents atherosclerosis by suppression of hepatic sterol regulatory element-binding protein-2 and induction of adiponectin in mice. <i>Circulation</i> , <b>2015</b> , 131, 1861-71	16.7	170
88	Metformin improves endothelial function in aortic tissue and microvascular endothelial cells subjected to diabetic hyperglycaemic conditions. <i>Biochemical Pharmacology</i> , <b>2015</b> , 98, 412-21	6	33
87	The answer is not 42. <i>Biochemical Pharmacology</i> , <b>2015</b> , 98, 327-34	6	4
86	MicroRNA Signature and Cardiovascular Dysfunction. <i>Journal of Cardiovascular Pharmacology</i> , <b>2015</b> , 65, 419-29	3.1	23
85	Challenges in the Biomedical Research Enterprise in the 21st century: Antecedents in the writings of David Triggler. <i>Biochemical Pharmacology</i> , <b>2015</b> , 98, 342-59	6	6
84	FGF21 maintains glucose homeostasis by mediating the cross talk between liver and brain during prolonged fasting. <i>Diabetes</i> , <b>2014</b> , 63, 4064-75	0.9	165
83	Proteinase-activated receptors 1 and 2 and the regulation of porcine coronary artery contractility: a role for distinct tyrosine kinase pathways. <i>British Journal of Pharmacology</i> , <b>2014</b> , 171, 2413-25	8.6	9
82	Cardiovascular impact of drugs used in the treatment of diabetes. <i>Therapeutic Advances in Chronic Disease</i> , <b>2014</b> , 5, 245-68	4.9	46
81	Metformin modulates hyperglycaemia-induced endothelial senescence and apoptosis through SIRT1. <i>British Journal of Pharmacology</i> , <b>2014</b> , 171, 523-35	8.6	154
80	Peroxynitrite Biology <b>2014</b> , 207-242		4

79	Proteinase-activated receptors, PAR1 & PAR2, regulate porcine coronary contractility via tyrosine kinase-MAPKinase signaling involving a cyclooxygenase (COX)-1 product. <i>FASEB Journal</i> , <b>2013</b> , 27, 880.2 <sup>0.9</sup>		
78	Metformin modulates hyperglycemia-induced endothelial dysfunction through SIRT1. <i>FASEB Journal</i> , <b>2013</b> , 27, lb612	0.9	
77	The endothelium: influencing vascular smooth muscle in many ways. <i>Canadian Journal of Physiology and Pharmacology</i> , <b>2012</b> , 90, 713-38	2.4	154
76	Endothelial dysfunction in diabetes mellitus: possible involvement of endoplasmic reticulum stress?. <i>Experimental Diabetes Research</i> , <b>2012</b> , 2012, 481840		75
75	The contribution of d-tubocurarine-sensitive and apamin-sensitive K-channels to EDHF-mediated relaxation of mesenteric arteries from eNOS <sup>-/-</sup> mice. <i>Journal of Cardiovascular Pharmacology</i> , <b>2012</b> , 59, 413-25	3.1	1
74	The endothelium in compliance and resistance vessels. <i>Frontiers in Bioscience - Scholar</i> , <b>2011</b> , 3, 730-44	2.4	23
73	Perivascular adipose tissue-derived relaxing factors: release by peptide agonists via proteinase-activated receptor-2 (PAR2) and non-PAR2 mechanisms. <i>British Journal of Pharmacology</i> , <b>2011</b> , 164, 1990-2002	8.6	14
72	A review of endothelial dysfunction in diabetes: a focus on the contribution of a dysfunctional eNOS. <i>Journal of the American Society of Hypertension</i> , <b>2010</b> , 4, 102-15		70
71	Endothelial dysfunction in diabetes: multiple targets for treatment. <i>Pflugers Archiv European Journal of Physiology</i> , <b>2010</b> , 459, 977-94	4.6	79
70	A role for nitroxyl (HNO) as an endothelium-derived relaxing and hyperpolarizing factor in resistance arteries. <i>British Journal of Pharmacology</i> , <b>2009</b> , 157, 540-50	8.6	100
69	Endothelium-dependent vasodilation in myogenically active mouse skeletal muscle arterioles: role of EDH and K(+) channels. <i>Microcirculation</i> , <b>2009</b> , 16, 377-90; 1 p following 390	2.9	19
68	Defying the economists: a decrease in heart rate improves not only cardiac but also endothelial function. <i>British Journal of Pharmacology</i> , <b>2008</b> , 154, 727-8	8.6	10
67	Effects of a Western diet versus high glucose on endothelium-dependent relaxation in murine micro- and macro-vasculature. <i>European Journal of Pharmacology</i> , <b>2008</b> , 601, 111-7	5.3	24
66	The early effects of elevated glucose on endothelial function as a target in the treatment of type 2 diabetes. <i>Timely Topics in Medicine Cardiovascular Diseases [electronic Resource]</i> , <b>2008</b> , 12, E3		5
65	Oxidative stress and increased eNOS and NADPH oxidase expression in mouse microvessel endothelial cells. <i>Journal of Cellular Physiology</i> , <b>2007</b> , 212, 682-9	7	78
64	Increased oxidative stress in the streptozotocin-induced diabetic apoE-deficient mouse: changes in expression of NADPH oxidase subunits and eNOS. <i>European Journal of Pharmacology</i> , <b>2007</b> , 561, 121-8	5.3	54
63	Nitrosothiol stores in vascular tissue: modulation by ultraviolet light, acetylcholine and ionomycin. <i>European Journal of Pharmacology</i> , <b>2007</b> , 560, 183-92	5.3	24
62	Calcium-activated potassium channel and connexin expression in small mesenteric arteries from eNOS-deficient (eNOS <sup>-/-</sup> ) and eNOS-expressing (eNOS <sup>+/+</sup> ) mice. <i>European Journal of Pharmacology</i> , <b>2007</b> , 560, 193-200	5.3	14

61	Widespread vascular production of C-reactive protein (CRP) and a relationship between serum CRP, plaque CRP and intimal hypertrophy. <i>Atherosclerosis</i> , <b>2007</b> , 191, 175-81	3.1	33
60	Vascular dysfunction in type 2 diabetic TallyHo mice: role for an increase in the contribution of PGH <sub>2</sub> /TxA <sub>2</sub> receptor activation and cytochrome p450 products. <i>Canadian Journal of Physiology and Pharmacology</i> , <b>2007</b> , 85, 404-12	2.4	22
59	The early effects of elevated glucose on endothelial function as a target in the treatment of type 2 diabetes. <i>Drugs of Today</i> , <b>2007</b> , 43, 815-26	2.5	7
58	What is the future of peer review? Why is there fraud in science? Is plagiarism out of control? Why do scientists do bad things? Is it all a case of: "all that is necessary for the triumph of evil is that good men do nothing"?. <i>Vascular Health and Risk Management</i> , <b>2007</b> , 3, 39-53	4.4	34
57	Pharmacological characteristics of endothelium-derived hyperpolarizing factor-mediated relaxation of small mesenteric arteries from db/db mice. <i>European Journal of Pharmacology</i> , <b>2006</b> , 551, 98-107	5.3	42
56	Novel role for K <sup>+</sup> -dependent Na <sup>+</sup> /Ca <sup>2+</sup> exchangers in regulation of cytoplasmic free Ca <sup>2+</sup> and contractility in arterial smooth muscle. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , <b>2006</b> , 291, H1226-35	5.2	39
55	A nonthiazolidinedione peroxisome proliferator-activated receptor gamma agonist reverses endothelial dysfunction in diabetic (db/db <sup>-/-</sup> ) mice. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2006</b> , 316, 364-70	4.7	8
54	Enhanced vascular reactivity of small mesenteric arteries from diabetic mice is associated with enhanced oxidative stress and cyclooxygenase products. <i>British Journal of Pharmacology</i> , <b>2005</b> , 144, 953-60	8.6	78
53	Endothelial dysfunction in the streptozotocin-induced diabetic apoE-deficient mouse. <i>British Journal of Pharmacology</i> , <b>2005</b> , 146, 1110-8	8.6	86
52	Twenty-five years since the discovery of endothelium-derived relaxing factor (EDRF): does a dysfunctional endothelium contribute to the development of type 2 diabetes?. <i>Canadian Journal of Physiology and Pharmacology</i> , <b>2005</b> , 83, 681-700	2.4	24
51	Endothelial dysfunction in Type 2 diabetes correlates with deregulated expression of the tail-anchored membrane protein SLMAP. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , <b>2005</b> , 289, H206-11	5.2	17
50	The vascular endothelium in diabetes: a practical target for drug treatment?. <i>Expert Opinion on Therapeutic Targets</i> , <b>2005</b> , 9, 101-17	6.4	18
49	Cytochrome P450 products and arachidonic acid-induced, non-store-operated, Ca <sup>2+</sup> entry in cultured bovine endothelial cells. <i>Endothelium: Journal of Endothelial Cell Research</i> , <b>2005</b> , 12, 153-61		6
48	Endothelial cell dysfunction and the vascular complications associated with type 2 diabetes: assessing the health of the endothelium. <i>Vascular Health and Risk Management</i> , <b>2005</b> , 1, 55-71	4.4	80
47	2-furoyl-LIGRLO-amide: a potent and selective proteinase-activated receptor 2 agonist. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2004</b> , 309, 1124-31	4.7	114
46	The endothelium in health and disease: A discussion of the contribution of non-nitric oxide endothelium-derived vasoactive mediators to vascular homeostasis in normal vessels and in type II diabetes. <i>Molecular and Cellular Biochemistry</i> , <b>2004</b> , 263, 21-7	4.2	21
45	Hyperpolarization of murine small caliber mesenteric arteries by activation of endothelial proteinase-activated receptor 2. <i>Canadian Journal of Physiology and Pharmacology</i> , <b>2004</b> , 82, 1103-12	2.4	30
44	Endothelium-Derived Hyperpolarizing Factor(s). Does it Exist and What Role Does it Play in the Regulation of Blood Flow?. <i>Progress in Experimental Cardiology</i> , <b>2004</b> , 341-348		

43	The endothelium in health and disease: a discussion of the contribution of non-nitric oxide endothelium-derived vasoactive mediators to vascular homeostasis in normal vessels and in type II diabetes. <i>Molecular and Cellular Biochemistry</i> , <b>2004</b> , 263, 21-7	4.2	7
42	The endothelium in health and disease--a target for therapeutic intervention. <i>Journal of Smooth Muscle Research</i> , <b>2003</b> , 39, 249-67	0.4	77
41	Endothelial cell dysfunction in type I and II diabetes: The cellular basis for dysfunction. <i>Drug Development Research</i> , <b>2003</b> , 58, 28-41	5.1	11
40	Contribution of EDHF and the role of potassium channels in the regulation of vascular tone. <i>Drug Development Research</i> , <b>2003</b> , 58, 81-89	5.1	3
39	Searching for the physiological role and therapeutic potential of vascular proteinase-activated receptor-2 (PAR2). <i>Drug Development Research</i> , <b>2003</b> , 60, 14-19	5.1	2
38	A photosensitive vascular smooth muscle store of nitric oxide in mouse aorta: no dependence on expression of endothelial nitric oxide synthase. <i>British Journal of Pharmacology</i> , <b>2003</b> , 138, 932-40	8.6	26
37	Chronic oral supplementation with sepiapterin prevents endothelial dysfunction and oxidative stress in small mesenteric arteries from diabetic (db/db) mice. <i>British Journal of Pharmacology</i> , <b>2003</b> , 140, 701-6	8.6	74
36	Catalase has negligible inhibitory effects on endothelium-dependent relaxations in mouse isolated aorta and small mesenteric artery. <i>British Journal of Pharmacology</i> , <b>2003</b> , 140, 1193-200	8.6	55
35	Endothelium-derived reactive oxygen species: their relationship to endothelium-dependent hyperpolarization and vascular tone. <i>Canadian Journal of Physiology and Pharmacology</i> , <b>2003</b> , 81, 1013-28	8.4	70
34	Endothelium-derived hyperpolarizing factor: is there a novel chemical mediator?. <i>Clinical and Experimental Pharmacology and Physiology</i> , <b>2002</b> , 29, 153-60	3	34
33	Multiple mechanisms of vascular smooth muscle relaxation by the activation of proteinase-activated receptor 2 in mouse mesenteric arterioles. <i>British Journal of Pharmacology</i> , <b>2002</b> , 135, 155-69	8.6	67
32	Cellular basis of endothelial dysfunction in small mesenteric arteries from spontaneously diabetic (db/db -/-) mice: role of decreased tetrahydrobiopterin bioavailability. <i>British Journal of Pharmacology</i> , <b>2002</b> , 136, 255-63	8.6	147
31	NO and the vasculature: where does it come from and what does it do?. <i>Heart Failure Reviews</i> , <b>2002</b> , 7, 423-45	5	20
30	Proteinase-activated receptor-2 (PAR2): vascular effects of a PAR2-derived activating peptide via a receptor different than PAR2. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2002</b> , 303, 985-92	4.7	35
29	Endothelin blockade potentiates endothelial protective effects of ACE inhibitors in saphenous veins. <i>Annals of Thoracic Surgery</i> , <b>2002</b> , 73, 1185-8	2.7	12
28	Vasorelaxant effects of a nitric oxide-releasing aspirin derivative in normotensive and hypertensive rats. <i>British Journal of Pharmacology</i> , <b>2001</b> , 133, 1314-22	8.6	49
27	Vascular smooth muscle relaxation mediated by nitric oxide donors: a comparison with acetylcholine, nitric oxide and nitroxyl ion. <i>British Journal of Pharmacology</i> , <b>2001</b> , 134, 463-72	8.6	95
26	Augmentation of endothelial function by endothelin antagonism in human saphenous vein conduits. <i>Journal of Neurosurgery</i> , <b>2001</b> , 94, 281-6	3.2	11

25	Endothelium-derived relaxing factors: A focus on endothelium-derived hyperpolarizing factor(s). <i>Canadian Journal of Physiology and Pharmacology</i> , <b>2001</b> , 79, 443-470	2.4	141
24	Endothelial Cell K <sup>+</sup> Channels, Membrane Potential and the Release of Vasoactive Factors from the Vascular Endothelium <b>2001</b> , 667-689		1
23	Selective cyclo-oxygenase-2 inhibition with celecoxib elevates blood pressure and promotes leukocyte adherence. <i>British Journal of Pharmacology</i> , <b>2000</b> , 129, 1423-30	8.6	94
22	Comparison of the pharmacological properties of EDHF-mediated vasorelaxation in guinea-pig cerebral and mesenteric resistance vessels. <i>British Journal of Pharmacology</i> , <b>2000</b> , 130, 1983-91	8.6	47
21	Lack of involvement of endothelin-1 in angiotensin II-induced contraction of the isolated rat tail artery. <i>British Journal of Pharmacology</i> , <b>2000</b> , 131, 1055-64	8.6	6
20	Novel endothelium-derived relaxing factors. Identification of factors and cellular targets. <i>Journal of Pharmacological and Toxicological Methods</i> , <b>2000</b> , 44, 441-52	1.7	17
19	Tetrahydrobiopterin improves endothelial function in human saphenous veins. <i>Journal of Thoracic and Cardiovascular Surgery</i> , <b>2000</b> , 120, 668-71	1.5	40
18	Antihypertensive properties of a nitric oxide-releasing naproxen derivative in two-kidney, one-clip rats. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , <b>2000</b> , 279, H528-35	5.2	27
17	Roles of calcium-activated and voltage-gated delayed rectifier potassium channels in endothelium-dependent vasorelaxation of the rabbit middle cerebral artery. <i>British Journal of Pharmacology</i> , <b>1998</b> , 123, 821-32	8.6	58
16	Dual endothelium-dependent vascular activities of proteinase-activated receptor-2-activating peptides: evidence for receptor heterogeneity. <i>British Journal of Pharmacology</i> , <b>1998</b> , 123, 1434-40	8.6	44
15	Cyclic GMP-dependent and cyclic GMP-independent actions of nitric oxide on the renal afferent arteriole. <i>British Journal of Pharmacology</i> , <b>1998</b> , 125, 563-9	8.6	33
14	Endothelium-dependent contractile actions of proteinase-activated receptor-2-activating peptides in human umbilical vein: release of a contracting factor via a novel receptor. <i>British Journal of Pharmacology</i> , <b>1998</b> , 125, 1445-54	8.6	40
13	Involvement of nitrosothiols, nitric oxide and voltage-gated K <sup>+</sup> channels in photorelaxation of vascular smooth muscle. <i>European Journal of Pharmacology</i> , <b>1998</b> , 347, 215-21	5.3	32
12	NO/PGI <sub>2</sub> -independent vasorelaxation and the cytochrome P450 pathway in rabbit carotid artery. <i>British Journal of Pharmacology</i> , <b>1997</b> , 120, 695-701	8.6	67
11	Cardiovascular effects of CPU-23, a novel L-type calcium channel blocker with a unique molecular structure. <i>British Journal of Pharmacology</i> , <b>1997</b> , 122, 1271-8	8.6	6
10	Novel Hantzsch 1,4-dihydropyridines to study the structure-function relationships of calcium channels and photoinduced relaxation. <i>Drug Development Research</i> , <b>1997</b> , 42, 120-130	5.1	6
9	Nitric oxide, a possible mediator of 1,4-dihydropyridine-induced photorelaxation of vascular smooth muscle. <i>British Journal of Pharmacology</i> , <b>1996</b> , 118, 879-84	8.6	11
8	Cardiovascular Pharmacology of CPU-23: A Novel Calcium Channel Blocker. <i>Cardiovascular Drug Reviews</i> , <b>1996</b> , 14, 364-379		0

7	Photosensitization of oesophageal smooth muscle by 3-NO <sub>2</sub> -1, 4-dihydropyridines: evidence for two cyclic GMP-dependent effector pathways. <i>British Journal of Pharmacology</i> , <b>1995</b> , 116, 3293-301	8.6	4
6	Mechanism of bile salt vasoactivity: dependence on calcium channels in vascular smooth muscle. <i>British Journal of Pharmacology</i> , <b>1994</b> , 112, 1209-15	8.6	20
5	The effects of perfusion rate and NG-nitro-L-arginine methyl ester on cirazoline- and KCl-induced responses in the perfused mesenteric arterial bed of rats. <i>British Journal of Pharmacology</i> , <b>1994</b> , 111, 13-20	8.6	27
4	Interactions of nitric oxide synthase inhibitors and dexamethasone with alpha-adrenoceptor-mediated responses in rat aorta. <i>British Journal of Pharmacology</i> , <b>1993</b> , 109, 495-501	8.6	27
3	The effects of alpha-adrenoceptor agonists on intracellular Ca <sup>2+</sup> levels in freshly dispersed single smooth muscle cells from rat tail artery. <i>British Journal of Pharmacology</i> , <b>1993</b> , 109, 1272-5	8.6	13
2	Varying Extracellular [K <sup>+</sup> ]. <i>Journal of Cardiovascular Pharmacology</i> , <b>1993</b> , 21, 423-429	3.1	248
1	Calcium antagonizes the magnesium-induced high affinity state of the hepatic vasopressin receptor for the agonist interaction. <i>British Journal of Pharmacology</i> , <b>1990</b> , 100, 5-10	8.6	3